TB-402

Generic Name: TB-402

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: -

Unique Ingredient Identifier: -

Background: TB-402 is a human antibody binding to Factor VIII, which plays a crucial role in the coagulation of the blood. It is expected to be developed as a potential treatment to prevent blood clot formation in connection with certain types of heart arrhythmia, such as atrial fibrillation.

Indication: Investigated for use/treatment in atrial fibrillation and thrombosis.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Single IV Administration of TB-402 for Prophylaxis of Venous Thromboembolic Events (VTE) After Total Hip Replacement Surgery

Phase 2

Completed

Conditions: Prophylaxis of Venous Thromboembolic Events

Interventions: Drug: Rivaroxaban
Drug: TB-402

First Posted Date: 2011-04-29

Last Posted Date: 2012-08-23

Lead Sponsor: ThromboGenics

Target Recruit Count: 632

Registration Number: NCT01344954

Locations: 🇦🇹
KRANKENHAUS DES BARMHER.SCHW.Linz, Linz, Austria
🇷🇺
Federal State Healthcare Institution: Clinical Hospital #122 named after L.G. Sokolov under the Federal Medical-Biological Agency of Russia, Saint-Petersburg, Russian Federation
🇧🇪
ZNA Antwerpen Locatie Middelheim, Antwerpen, Belgium

and more 33 locations

Single Intravenous Administration of TB-402 for the Prophylaxis of Venous Thromboembolic Events (VTE) After Total Knee Replacement Surgery

Phase 2

Completed

Conditions: Total Knee Replacement Surgery

Interventions: Drug: TB-402
Drug: Enoxaparin

First Posted Date: 2008-11-19

Last Posted Date: 2014-04-07

Lead Sponsor: ThromboGenics

Target Recruit Count: 316

Registration Number: NCT00793234

Locations: 🇺🇦
Cherkasska Regional Hospital. Department of Orthopedics and Traumatology., Cherkassy, Ukraine
🇷🇺
Saint Petersburg State Healthcare Institution "Municipal Multi-Speciality Hospital No. 2", Saint Petersburg, Russian Federation
🇺🇦
Ivano-Frankіvsk Regional Clinical Hospital, Department of ortopedics and traumatology., Ivano-Frankivsk, Ukraine

and more 32 locations

A Phase I Study of Monoclonal Antibody TB-402 in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: TB-402
Drug: Placebo

First Posted Date: 2008-02-11

Last Posted Date: 2014-04-07

Lead Sponsor: ThromboGenics

Target Recruit Count: 56

Registration Number: NCT00612196

Locations: 🇩🇰
Cyncron Clinical Research Unit, Copenhagen, Denmark

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy